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Abstract
Background: The role of intra- and extra-cranial venous system impairment in the pathogenesis of various vascular,
inflammatory and neurodegenerative neurological disorders, as well as in aging, has not been studied in detail. Nor have
risk factors been determined for increased susceptibility of venous pathology in the intra-cranial and extra-cranial veins. The
aim of this study was to investigate the association between presence of a newly proposed vascular condition called chronic
cerebrospinal venous insufficiency (CCSVI) and environmental factors in a large volunteer control group without known
central nervous system pathology.
Methods and Findings: The data were collected in a prospective study from 252 subjects who were screened for medical
history as part of the entry criteria and participated in the case-control study of CCSVI prevalence in multiple sclerosis (MS)
patients, and then were analyzed post-hoc. All participants underwent physical and Doppler sonography examinations, and
were assessed with a structured environmental questionnaire. Fullfilment of $2 positive venous hemodynamic (VH) criteria
on Doppler sonography was considered indicative of CCSVI diagnosis. Risk and protective factors associated with CCSVI
were analyzed using logistic regression analysis. Seventy (27.8%) subjects presented with CCSVI diagnosis and 153 (60.7%)
presented with one or more VH criteria. The presence of heart disease (p=.001), especially heart murmurs (p=.007), a
history of infectious mononucleosis (p=.002), and irritable bowel syndrome (p=.005) were associated with more frequent
CCSVI diagnosis. Current or previous smoking (p=.029) showed a trend for association with more frequent CCSVI diagnosis,
while use of dietary supplements (p=.018) showed a trend for association with less frequent CCSVI diagnosis.
Conclusions: Risk factors for CCSVI differ from established risk factors for peripheral venous diseases. Vascular, infectious
and inflammatory factors were associated with higher CCSVI frequency.
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Introduction
Several studies have shown a relationship between internal
jugular vein (IJV) drainage abnormalities and specific neurological
diseases of undetermined etiology such as transient global amnesia
[1], transient monocular blindness [2], cough headache [3],
primary exertional headache [4], idiopathic intra-cranial hyper-
tension [5] and higher prevalence of white matter hyperintensities
in elderly people.[6] The role of intra- and extra-cranial venous
system impairment in the pathogenesis of various vascular,
inflammatory and neurodegenerative neurological disorders, as
well as in aging, has not been studied in detail. Nor have risk
factors been determined for increased susceptibility of venous
pathology in the intra-cranial and extra-cranial veins. Certainly,
physiological inter-individual variation of the cerebral venous
anatomy and the complexity of imaging the venous systems,
regardless of the modality used, contribute to the lack of risk factor
studies in relation to the intra- and extra-cranial venous system.
Recently, a new vascular condition called chronic cerebrospinal
venous insufficiency (CCSVI) was proposed in patients with
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blood outflow from the central nervous system (CNS) to the
periphery, secondary to anatomical abnormalities of the major
neck and azygos veins [7]. So far, CCSVI has caused considerable
controversy and debate in the medical literature because: 1)
recently published studies [8–14] failed to reproduce the original
results that reported that CCSVI was never observed in controls,
but perfectly overlapped with the diagnosis of MS [7]; 2) of
uncritical application of interventional procedures in the treatment
of CCSVI-related abnormalities without established safety and
efficacy outcomes [15–17], and 3) it has been demonstrated that
CCSVI-related abnormalities are not exclusive to MS patients, but
healthy controls [11,13,18] or patients with other neurological
diseases [11] can also present with these anomalies.
The origin of CCSVI-related venous anomalies has not been
determined. It has been suggested that the origin of these abnor-
malities could be physiological [4,8], aging-dependent [6,19],
congenital [20], a possible consequence of an inflammatory pro-
cess [11], related to chronic pulmonary pathology such as chronic
obstructive pulmonary disease (COPD) and pulmonary hyperten-
sion [21] or related to environmental factors.
In the first phase of the Combined Trans-cranial and Extra-
cranial Venous Doppler (CTEVD) study that enrolled 499 par-
ticipants [11], CCSVI prevalence rates were 56.1% in MS
patients, 42.3% in those with other neurologic diseases, 38.1% in
clinically isolated syndrome (CIS) patients and 22.7% in controls.
Another recent study showed even higher prevalence of CCSVI in
controls (36%) [18].
Therefore, the aim of this study was to investigate the asso-
ciation between presence of CCSVI and risk/protective factors in
a large volunteer control group without known central nervous
system (CNS) pathology.
Methods
Subjects and clinical assessments
The study participants were controls without known CNS
pathology who were part of the prospective CTEVD study and
were analyzed post-hoc [11]. The study started in April 2009 and is
still enrolling controls, as well as patients with MS, CIS and with
other neurologic diseases. Controls were recruited from the following
volunteer sources: hospital personnel, respondents to a local news-
paper advertisement, and spouses or relatives of the MS patients.
Inclusion criteria were: fulfilling health screen questionaire re-
quirements containing information about medical history (illnesses,
surgeries, medications, etc.), fulfilling the health screen requirements
on physical examination, being capable of undergoing diagnostic
evaluation for intra- and extra-cranial venous system using Doppler
sonography (DS) and being able to respond on a structured
environmental questionnaire. Exclusion criteria included pre-existing
medical conditions known to be associated with brain pathology (e.g.,
neurodegenerative disorder, cerebrovascular disease, cognitive im-
pairment, history of psychiatric disorders, seizures, trauma, etc.), neck
pathology, history of cerebral congenital vascular malformations,
venous thrombosis, genetic thrombophilia and presence of arthritic
necks (as these subjects may not be able to lie flat).
All subjects underwent physical and DS examinations, and were
assessed with a structured environmental questionnaire adminis-
tered in-person by a trained interviewer unaware of subjects’ disease
status (Appendix S1). The questionnaire contained information
relatedtodemographiccharacteristics,presenceofautoimmuneand
other concomitant diseases, vascular risk factors and environmental
factors, as well as information about habits (Appendix S2). Race/
ethnicity was determined according to the US Census Bureau.
This study was approved by the local Health Sciences
Institutional Review Board (HSIRB #NEU2490109A) and written
informed consent was obtained from all subjects.
Doppler sonography
Participants underwent trans- and extra-cranial DS of the neck.
A Color-coded DS scanner (Esaote-Biosound, My lab 25)
equipped with a 7.5–10 Mhz transducer was used to examine
venous return in the IJVs and vertebral veins (VVs). The DS
examination was performed by two trained technologists who were
blinded to subjects’ characteristics, as previously reported [11].
The detailed scanning protocol and validation were recently
reported [11]. Briefly, the following 5 venous hemodynamic (VH)
parameters indicative of CCSVI were investigated: 1) Reflux/
bidirectional flow in the IJVs and/or in the VVs in sitting and in
supine positions, defined as flow directed towards the brain for a
duration of .0.88 s; 2) Reflux/bidirectional flow in the deep
cerebral veins defined as reverse flow for a duration of 0.5 s in one
of the intra-cranial veins; 3) B-mode abnormalities or stenoses in
IJVs. IJV stenosis is defined as a cross-sectional area (CSA) of this
vein #0.3 cm2; 4) Flow that is not Doppler-detectable in IJVs
and/or VVs despite multiple deep breaths, and 5) Reverted
postural control of the main cerebral venous outflow pathway by
measuring the difference of the CSA of the IJVs in the supine and
upright positions. A subject was considered CCSVI-positive if $2
VH criteria were fulfilled, as previously proposed [7].
Statistical analyses
Statistical analysis was performed using the Statistical Package
for Social Sciences (SPSS, version 16.0). Student’s t-test and the
chi-square test were used for comparing demographic and clinical
differences between the study subgroups, as appropriate. In order
to test whether CCSVI was dependent on age, the subjects were
divided into age groups, ranging from 0–10 years to 71–80 years,
and the differences were tested with the chi-square test. Individual
risk factors were investigated separately. Whenever possible, the
presence of multiple variables that investigated specific individual
risk factors was combined into a single variable (Appendix S2).
Logistic regression analysis was used to test which risk/protective
factors were associated with CCSVI diagnosis. The odds-ratio
(OR) and a 95% confidence interval (CI) were calculated.
To correct for multiple comparisons, a nominal p-value of
,0.01 was considered significant using two-tailed tests.
Results
Demographic and clinical characteristics
Table 1 shows demographic and clinical characteristics of the
study subjects. The mean age of subjects was 42.4615.3 years,
median was 44.5 years with a range of 60. One hundred forty-four
subjects were females (57.1%), and 82 (32.1%) of all participants
had a relative with MS diagnosis. No significant differences were
found in number, age and gender between participants, who were
selected from different recruitment sources (hospital personnel,
respondents to advertisement, MS spouses or MS relatives).
Of the 252 participants, 207 (82.1%) were Caucasian, 16 (6.3%)
were African-Americans, 4 (1.6%) were Asian, 2 (0.8%) were
Hispanic/Latino and data for 23 subjects were missing. The
majority of the participants (over 95%) were from Buffalo, NY.
Almost 1/3 of the subjects presented with one or more vascular
risk factors (ranging from 22.2% to 57.9%) and almost half of the
subjects (57.1%) were taking dietary supplements. Consumption of
alcohol (ranging from occasionally to daily) was very frequent
among participants (81%). Almost 2/3 of subjects practiced
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reported an autoimmune disease. Allergy was present in 35.7% of
participants and migraine in 15.9%.
CCSVI prevalence
Table 2 shows CCSVI prevalence in study subjects and the
gender differences for global and individual VH criteria. Seventy
(27.8%) subjects presented with $2 positive VH criteria and were
considered to have CCSVI. One or more positive VH criteria
were found in 153 (60.7%) participants. The most common
positive VH criterion was criterion 3 (B-mode abnormalities or
proximal stenoses in IJVs), which was present in 99 (39.3%) of the
subjects, followed by VH criterion 2 (reflux/bidirectional flow in
the DCVs), (20.2% of subjects).
There was no significant difference for CCSVI diagnosis and/or
presence of one or more positive VH criteria between males and
females. No difference was found for presence of CCSVI or one or
more positive VH criteria between different age groups (Figures 1a
and b). The prevalence of CCSVI was similar with respect to
source of recruitment.
Risk/protective factors
Table 3 shows risk and protective factors that were significantly
associated with the CCSVI diagnosis in logistic regression analysis.
Subjects who presented with heart disease generally (p=.001), and
especially heart murmurs (p=.007), a history of infectious
mononucleosis (p=.002) and irritable bowel syndrome (IBS)
(p=005) were significantly associated with higher frequency of
CCSVI diagnosis. There was a trend for association between higher
frequency of CCSVI diagnosis and use of fish oil (p=.015) or
current/previous smoking (p=.029). However, subanalysis showed
that 57 of the 71 subjects who used fish oil, also had heart disease
and weresmoking.There was a trend forlower frequency of CCSVI
in subjects who were using dietary supplements for three months or
more (p=.018) or those who were using ginkgo (p=.027).
Familial connection to MS, presence of rheumatoid disorders,
psoriasis, diabetes type 1, asthma, allergy, cancer, migraine,
COPD, obesity, hypertension, multiple pregnancies, occupation
requiring standing, use of alcohol or presence of other risk factors
were not associated with increased risk for CCSVI.
Discussion
This is the first study to investigate the association of
demographic, clinical and environmental risk factors and presence
of CCSVI in a large control group without known central nervous
system pathology. We found that heart disease (especially heart
murmurs), history of infectious mononucleosis, and IBS were
significantly associated with presence of CCSVI. There was also a
trend for higher prevalence of CCSVI in subjects who smoked or
consumed fish oil. We also found that use of dietary supplements
in general, as well as ginkgo by itself, were protective factors for
this vascular condition.
Debate is still ongoing about CCSVI and its relationship with
MS pathogenesis, because none of the confirmatory studies
[8–13,18] reproduced the originally reported results [7]. One of
Table 1. Demographic and clinical characteristics in study
subjects.
Subjects
n( % )
Female
n( % )
Age years
Mean (SD)
Population 252 144 (57.1) 42.4 (15.3)
Race/Ethnicity
Caucasian 207 (82.1) 109 (53.4) 43.8 (15.4)
African-American 16 (6.3) 12 (66.7) 37.3 (10)
Hispanic/Latino 2 (0.8) 1 (50) 28 (14.1)
Asian 4 (1.6) 3 (75) 33.5 (19.1)
Other/missing 23 (9.1) 19 (13.2) 35.7 (11)
Vascular risk factors
Heart disease 80 (31.7) 45 (31.3) 43.3 (15.2)
Smoking 146 (57.9) 35 (24.3) 41.9 (15.4)
Hypertension 64 (25.4) 29 (20.1) 48.6 (14.9)
Obesity 56 (22.2) 34 (23.6) 46 (13.5)
Habits
Alcohol 204 (81) 112 (54.9) 44.2 (13.7)
Dietary supplements 144 (57.1) 90 (62.5) 44.4 (15.04)
Herbal supplements 39 (15.5) 26 (66.7) 41.8 (12.6)
Physical activity 168 (66.7) 87 (60.4) 40.6 (15.9)
Autoimmune diseases
Rheumatoid disorders 8 (3.2) 4 (50) 52.1 (7.1)
Psoriasis 6 (2.4) 4 (66.6) 49.2 (17.3)
Diabetes Mellitus Type 1 5 (2) 3 (60) 51.5 (5.2)
Other diseases
Asthma 32 (12.7) 22 (68.7) 43.7 (16.6)
Allergy 90 (35.7) 62 (68.8) 42.6 (15.7)
Cancer 14 (5.7) 7 (50) 53.7 (6.4)
COPD 9 (3.6) 7 (77.7) 52 (11.9)
Irritable bowel syndrome 19 (7.5) 11 (57.9) 45.9 (12.06)
Migraine 40 (15.9) 28 (70) 42.4 (13.5)
Legend: COPD – chronic obstructive pulmonary disease.
The various environmental factor frequencies were calculated on the total
population of 252 subjects. Data for missing cases were conservatively
categorized as negative.
doi:10.1371/journal.pone.0028062.t001
Table 2. CCSVI prevalence in study subjects on Doppler
sonography.
CCSVI criteria
Total
(n=252)
Females
(n=144)
Males
(n=108) p
VH Criterion 1, n (%) 36 (14.3) 18 (12.5) 18 (16.7) .225
VH Criterion 2, n (%) 51(20.2) 31 (21.5) 20 (18.5) .335
VH Criterion 3, n (%) 99 (39.3) 51 (35.4) 48 (44.4) .093
VH Criterion 4, n (%) 31(12.3) 14 (9.7) 17 (15.7) .107
VH Criterion 5, n (%) 21 (8.3) 11 (7.6) 10 (9.3) .406
$2 VH positive
criteria, n (%)
70 (27.8) 36 (25) 34 (31.5) .160
$1 VH positive
criteria, n (%)
153 (60.7) 85 (59) 68 (63) .308
Legend: CCSVI – chronic cerebrospinal venous insufficiency; VH - venous
hemodynamic criteria.
Subjects who fulfilled exactly one of the 4 VH criteria and were not assessed on
one VH criterion were classified originally as CCSVI borderline [11]. In the
present study, 21 (8.3%) fell into this category. These individuals were
conservatively categorized as CCSVI negative in the statistical analyses,
potentially biasing associations toward the null.
CCSVI frequency differences between males and females were tested using the
chi-square test.
doi:10.1371/journal.pone.0028062.t002
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lack of standardized diagnostic guidelines related to the evaluation
of the intra- and extra-cranial cerebrospinal venous system and the
definition of pathology related to those anomalies. So far, it has not
been possible to determine whether venous abnormalities are
related to MS or are a consequence of MS. The higher prevalence
of CCSVI in progressive MS patients may suggest that CCSVI
may play a contributory role or be a consequence of disease
progression [11].
Furthermore, there is still a lack of information about the
prevalence of CCSVI in patients with other neurological and non-
neurological diseases of autoimmune or other origins. In a recently
published study, it was reported that prevalence of CCSVI was
higher in patients with other neurologic diseases than in healthy
individuals [11]. In that study, 42.3% of the patients with other
neurologic diseases presented with CCSVI. However, the
composition of the other neurologic disease group was biased
towards immune mediated or inflammatory diseases. Therefore at
this time, it cannot be excluded that prevalence of CCSVI may be
increased in patients presenting with autoimmune neurologic and
non-neurologic diseases in general. Further studies need to
determine whether CCSVI is an MS-specific condition or can
be found with high prevalence in neurologic and non-neurologic
pathologic entities.
Because several recently published studies detected a substantial
amount of vein abnormalities in the general population [11,13,18]
ranging from 22% to 40%, we aimed to investigate which risk
factors could be associated with the presence of CCSVI. In the
present study, 27.8% of the subjects presented with CCSVI.
It is well known that established risk factors for periphery vein
disorders include older age, family history, female gender, multiple
pregnancies, an occupation requiring standing, and obesity in
females [22]. In our study we did not find an association between
these risk factors and CCSVI. In addition, there was no
correlation between different age groups and CCSVI diagnosis,
although increased prevalence of CCSVI and one or more VH
Figure 1. Prevalence of CCSVI diagnosis (a) or more than one venous hemodynamic criterion (b) in study subjects, according to the
age group.
doi:10.1371/journal.pone.0028062.g001
Table 3. Risk factors significantly associated with CCSVI in the logistic regression analysis.
Risk factors Subjects (n=252) (totR/totA/CCSVI) OR 95% CI R p
Heart disease 227/80/32 2.7 1.5–4.96 .99 .001**
Heart murmurs 227/13/8 4.9 1.5–15.5 1.5 .007**
Infective mononucleosis 230/34/18 2.7 1.4–5.4 1.0 .002**
Irritable bowel syndrome 234/19/11 3.9 1.5–10.2 1.4 .005**
Fish oil 131/72/21 2.3 1.1–4.8 .853 .015*
Smoking 218/146/50 1.98 1.0–3.8 .683 .029*
Protective factors Subjects (n=252) (totR/totA/no CCSVI) OR 95% CI R p
Dietary supplements 232/144/49 0.5 0.27–0.93 2.7 .018*
Gingko 32/10/8 0.1 0.02–0.8 21.9 .027*
Legend: totR - total respondents on the environmental questionnaire; totA - total affected for certain condition; CCSVI - subjects presenting with CCSVI; no CCSVI -
subjects not presenting with CCSVI; OR - odds ratio; CI - confidence interval; R - regression coefficient.
*represents a trend for significance (p,0.05);
**represents significance (p,0.01).
doi:10.1371/journal.pone.0028062.t003
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is in line with a recent study that investigated IJV hemodynamics
and the frequency of jugular venous reflux in a large cohort of
elderly subjects, and reported increased prevalence of jugular
venous reflux, dilated vessel lumen and slowed flow velocity in the
left IJV, as well as decreased time-averaged mean velocity of
bilateral IJV, in those over 70 years of age [19]. It has also been
found that the prevalence of peripheral chronic venous insuffi-
ciency increases with aging [22].
One of the most interesting findings of the present study was
that subjects who had a history of infectious mononucleosis
showed higher frequency of CCSVI diagnosis. It is known that the
Epstein-Barr virus (EBV) infection has been associated with
numerous cancers. There is also considerable evidence that EBV
infection is the most important risk factor candidate for the
development of MS [23]. MS risk is low in individuals who are
EBV negative, but increases several fold following EBV infection.
There is some evidence suggesting that EBV infection can act as a
precipitating factor for venous thrombo-embolism in immuno-
compromised patients [24]. The mechanisms by which EBV
infection might trigger thrombosis are not fully understood, but
include transient elevations of anti-phospholipid antibodies [25],
and EBV-induced oxidative endothelial cell injury [26]. The EBV
virus was also found to have caused venous thrombosis in a patient
with hereditary thrombophilia [24]. Persistent EBV infection in
the small vein vessel wall can directly promote a pro-inflamma-
tory, pro-coagulant, and pro-atherogenic environment [24].
Whether EBV infection may damage the venous endothelium,
causing venous thromboses and strictures in the cranial and spinal
venous drainage system, is unknown at this time. It could also be
hypothesized that an EBV-mediated autoimmune attack of the
intra- and extra-cranial veins can cause chronic inflammation and
scarring [27]. Further longitudinal studies should investigate the
relationship between CCSVI and EBV infection.
We found a significant association between CCSVI diagnosis
and the presence of IBS. Previous studies have suggested that
patients with IBS have increased risk of venous thrombo-embolism
[28]. Serum markers associated with inflammation have also been
found in patients with IBS [29]. Patients with MS and their first-
degree relatives seem to be at an increased risk of acquiring certain
other autoimmune diseases [30]. The risk of developing MS was
1.7 times higher for individuals who had IBS compared with those
who did not [31].
The current study also identified an association between CCSVI
and the presence of heart disease and, in particular, the presence of
heart murmurs. Patients with cardiovascular events are at short-
term increased risk of venous thrombo-embolism [32]. There is
increasing evidence that arterial and venous thrombosis share
several cardiovascular risk factors [33]. The pathogenesis of both
disorders includes endothelial injury, platelet activation, elevated
levels of intrinsic clotting factors and inflammatory markers,
increased fibrinogen, and impaired fibrinolysis [34]. MS patients
may have a higher risk for cardiovascular disease than the general
population [35]. It has been reported that vascular co-morbidity is
associated with more rapid disability progression [36] and higher
risk of death [37] in patients with MS. However, as our original
environmental questionnaire was biased toward risk factors for MS,
we did not collect general risk factors in relatives of the healthy
individual (except high blood pressure). No relationship between
CCSVI and high blood pressure was found in the present study.
There was a trend in the present study for higher prevalence of
CCSVI in subjects who were or currently are smokers. It has been
shown that cigarette smoking is one of the most important risk
factors for vascular disease in women [38]. The mechanisms
responsible for the harmful effects of tobacco on the venous system
have still not been elucidated. However, cigarette smoking is
known to be a major factor of hypoxia through fixation of carbon
monoxide and nitric oxide to hemoglobin [39]. Also, it damages
the vascular endothelium, promotes vascular thrombosis, increases
the relative risk of venous thrombo-embolism and is significantly
associated with lower limb venous insufficiency [40]. Cigarette
smoking is one of the most compelling risk factors associated with
increased risk of developing [41] and progression [42] of MS.
A trend for relationship between higher prevalence of CCSVI
and use of fish oil was identified in the current study. This finding
has to be interpreted with caution, as only 52% of participants
provided an answer to this question and 80.3% of those who used
fish oil also presented heart disease and were smoking. Therefore,
these preliminary findings need further investigation, but could
indicate that use of fish oil showed a trend for higher CCSVI
frequency, because it was used in subjects who already had other
risk factors for CCSVI. Marine fish consumption is known to
reduce mortality from ischemic heart disease [43]. The use of fish
oil as a dietary supplement, however, is not universally
recommended. In large doses, fish oil reduces plasma cholesterol
and triacylglycerol, but increases low-density lipoprotein levels and
the potential for free radical generation and bleeding [44]. In
animal models of arterial thrombosis, fish-oil-enriched diets have
been shown to have an antithrombotic effect, if the fish-oil
consumption is associated with a reduction of the saturated fat
intake [45].
Between 10% to 20% of people with MS have a relative with
the disease, suggesting a genetic link [46]. The CTEVD study was
designed to test whether MS relatives more frequently present with
CCSVI diagnosis, but no relationship was found in a previous [11]
or this study.
Among protective factors, we found that everyday use of dietary
supplements showed a trend for lower frequency of CCSVI.
Dietary supplements are widely used for improving the integrity
and function of veins in the lower limbs, in order to increase the
integrity of the tissue to improve the vein’s function [47]. They
also decrease the capillary’s permeability by reducing the number
and size of pores in the capillary’s walls, improve the tone of or
dilate the blood vessels and affect blood-clotting mechanisms [47].
In particular, we found that use of ginkgo showed a trend for a
protective role in relation to CCSVI; however, because only 13%
of participants answered this question, the data need to be
confirmed in further studies. Ginkgo may reduce the risk of
atherosclerosis by interfering with the receptor of the platelet
activating factor in human cells [48]. Ginkgo also increases blood
circulation to the brain, arms, and legs [49]. Ginkgo biloba is able
to prevent the activation of endothelial cells, which play a key role
in regulating vascular homeostasis, by hypoxic conditions both in a
cell culture and in a complete perfused saphenous vein [50].
One of the limitations of our study is the small number of subjects
representing races other than Caucasian. Also, there was a small
number of participants who used dietary supplements such as
gingko and fish oil as well as a low number of respondents for some
questions; these could have influenced the results about risk and
protective factors for CCSVI in relation to those variables. Another
limit could be related to ourdecision to select controls from different
sources of recruitment. Spouses or relatives of MS patients may
have shared environmental risk factors with MS patients; however,
no CCSVI prevalence differences were found according to the
source of recruitment. Further studies enrolling a larger cohort of
controls are needed to determine the role of risk factors for CCSVI.
In conclusion, our study showed that risk factors for CCSVI
differ from established risk factors for peripheral venous diseases.
Risk Factors for CCSVI in Control Volunteers
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